OR WAIT null SECS
Bayer Healthcare, Bristol-Myers Squibb, Sucampo Pharmaceuticals, Takeda Pharmaceuticals, and Horizon Pharma representatives join PhRMA board.
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced the election of five of its newest members to its Board of Directors on June 16.
“Over the past couple of months, we have been pleased to welcome five exceptional leaders to PhRMA’s Board,” said John J. Castellani, PhRMA president and chief executive officer in a statement. “Our organization will benefit not only from their deep understanding of the economic, regulatory and legislative issues facing our industry, but also from the global perspective, tested leadership and proven industry success they will bring to bear to help guide PhRMA’s work in the coming years.”
PhRMA’s newest board members include:â¨Werner Baumann, Chairman of the Board of Management, Bayer HealthCare AG; Giovanni Caforio, M.D., Chief Executive Officer, Bristol-Myers Squibb Company; Peter Greenleaf, Chief Executive Officer, Sucampo Pharmaceuticals, Inc.; Ramona Sequeira, President, Takeda Pharmaceuticals U.S.A., Inc.; and Timothy P. Walbert, Chairman, President & Chief Executive Officer, Horizon Pharma plc